TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32676976

Group type: EXPERIMENTAL
Intervention: Keguan-1 19.4 g twice daily plus control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Number of subjects: 48
Study: 35367661

Group type: EXPERIMENTAL
Intervention: Mesor per 10 beats per min increase
Number of subjects: 6201

Group type: EXPERIMENTAL
Intervention: Amplitude per 5 bpm increase
Number of subjects: 6201

Group type: EXPERIMENTAL
Intervention: Peak time reached between 12:00-18:00
Number of subjects: 6201

Group type: EXPERIMENTAL
Intervention: Combining APACHE IV score and circadian rhythm variables
Number of subjects: 6201
Study: 33757646

Group type: EXPERIMENTAL
Intervention: Renin–angiotensin–aldosterone system blockers
Number of subjects: 0
Study: 35660270

Group type: EXPERIMENTAL
Intervention: Infant massage applied for 10 minutes before phototherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Infant massage
Number of subjects: 61
Study: 34175006

Group type: EXPERIMENTAL
Intervention: Pre-pandemic mental health assessments (baseline and 8-month follow-ups)
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Post-pandemic mental health assessments (8-month follow-up during early stages of the pandemic)
Number of subjects: 1376
Study: 34107828

Group type: EXPERIMENTAL
Intervention: One IPL treatment followed by three diode laser treatments
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two IPL treatments followed by three diode laser treatments
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Three IPL treatments followed by three diode laser treatments
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diode laser (control group)
Number of subjects: 45
Study: 36339420

Group type: EXPERIMENTAL
Intervention: 1, 2, 4, 8, or 12 µg/day CG beta plus rFSH
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: CG beta (highest dose group)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: CG beta
Number of subjects: 619
Study: 32374623

Group type: EXPERIMENTAL
Intervention: NUC-1031 (725 mg/m2)/cisplatin (25 mg/m2)
Number of subjects: 828

Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2)
Number of subjects: 828
Study: 33417321

Group type: COMPARATOR
Intervention: RAD51 variants G135C and G172T in breast cancer tissue
Number of subjects: 103

Group type: COMPARATOR
Intervention: RAD51 expression in malignant cells
Number of subjects: 103

Group type: COMPARATOR
Intervention: G135C and C135C variants
Number of subjects: 103

Group type: COMPARATOR
Intervention: G172T variant
Number of subjects: 103

Group type: COMPARATOR
Intervention: G135C and C135C genotypes in triple-negative breast cancer
Number of subjects: 103
Study: 32316391

Group type: EXPERIMENTAL
Intervention: High-nucleotide mycoprotein (H-NU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nucleotide-depleted mycoprotein (L-NU)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both interventions (H-NU and L-NU)
Number of subjects: 10
Study: 33894335

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus pemetrexed–platinum
Number of subjects: 616

Group type: COMPARATOR
Intervention: placebo plus pemetrexed–platinum
Number of subjects: 616
Study: 33069606

Group type: EXPERIMENTAL
Intervention: Consumer co-created infographic about physical activity during a gestational diabetes pregnancy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (gestational diabetes education alone)
Number of subjects: 69
Study: 35972834

Group type: EXPERIMENTAL
Intervention: Cream with glucocorticosteroid and fusidic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo cream with fusidic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific skin care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient and Observer Scar Assessment Scale (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient and Observer Scar Assessment Scale (control group)
Number of subjects: 0
Study: 34062140

Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily and 39.5 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35296414

Group type: EXPERIMENTAL
Intervention: Online naloxone training
Number of subjects: 220

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 220
Study: 34429089

Group type: EXPERIMENTAL
Intervention: Smartphone application including BSE reminder, training, alarm, and feedback to the therapist, educational movies, and self-assessment.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no smartphone application).
Number of subjects: 150
Study: 32829109

Group type: EXPERIMENTAL
Intervention: HIIT: high-intensity interval training (10× 1 bout: 1 min − 100% Maximal Aerobic Velocity)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MICT: moderate-intensity continuous training (65% Maximal Aerobic Velocity; kcal equal to HIIT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LPS-stimulated release after both acute MICT and HIIT exercise sessions
Number of subjects: 22
Study: 35347875

Group type: EXPERIMENTAL
Intervention: Champ4Life’s intervention (n=49)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 94
Study: 33097408

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) as a continuous variable
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) in the second tertile
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) in the third tertile
Number of subjects: 652
Study: 32725107

Group type: EXPERIMENTAL
Intervention: Continuous anticoagulation with apixaban
Number of subjects: 678

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 678
Study: 35366354

Group type: EXPERIMENTAL
Intervention: +0.50 DS blur
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: +0.75 DS blur
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: +1.00 DS blur
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: +1.25 DS blur
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Blur
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: +1.25 DS blur (yellow signals)
Number of subjects: 30
Study: 32811741

Group type: EXPERIMENTAL
Intervention: Johrei treatment
Number of subjects: 0
Study: 34825739

Group type: EXPERIMENTAL
Intervention: PainReApp mHealth system with a physical activity program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Program information in paper format (control group)
Number of subjects: 100
Study: 34388360

Group type: EXPERIMENTAL
Intervention: BI 695501 (40 mg/0.8 mL formulation)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Adalimumab reference product (40 mg/0.4 mL or 40 mg/0.8 mL)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 147

Group type: COMPARATOR
Intervention: Adalimumab reference product
Number of subjects: 147
Study: 35244757

Group type: EXPERIMENTAL
Intervention: multi‐component self‐regulation intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: information‐only control
Number of subjects: 151
Study: 33157008

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic genomic sequencing
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Follow-up on genomic results
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Positive tests/genomic diagnosis
Number of subjects: 117
Study: 35338469

Group type: EXPERIMENTAL
Intervention: Upacicalcet 0.01 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Upacicalcet 0.1 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Upacicalcet 1.0 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Upacicalcet 2.5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 33877413

Group type: EXPERIMENTAL
Intervention: Non-university hospital departments
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: University hospital departments
Number of subjects: 172
Study: 32707325

Group type: EXPERIMENTAL
Intervention: Eclipse shoulder prosthesis
Number of subjects: 327

Group type: COMPARATOR
Intervention: Univers II shoulder prosthesis
Number of subjects: 327
Study: 34140055

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study: 32289829

Group type: EXPERIMENTAL
Intervention: Opioids with bupivacaine (O + B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Opioids without bupivacaine (O)
Number of subjects: 17
Study: 35718502

Group type: EXPERIMENTAL
Intervention: Jingfang Granules
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (Jingfang Granules simulation agent)
Number of subjects: 138
Study: 34905449

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HST) intervention provided to pregnant women
Number of subjects: 1618
Study: 35908980

Group type: EXPERIMENTAL
Intervention: Educational intervention based on a training booklet approved by cancer specialists
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 80
Study: 32909190

Group type: EXPERIMENTAL
Intervention: Starting progesterone luteal support (P4-LS) on day of egg retrieval (ER)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Starting progesterone luteal support (P4-LS) on day of embryo transfer (ET)
Number of subjects: 171
Study: 32048918

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TDN) combined with manual therapy (MT) and exercise (Ex)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Manual therapy (MT) and exercise (Ex)
Number of subjects: 22
Study: 33685703

Group type: EXPERIMENTAL
Intervention: High-lactose milk replacer (HL; 17% fat; 44% lactose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-fat milk replacer (HF; 23% fat; 37% lactose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-lactose milk replacer (HL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-fat milk replacer (HF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 32
Study: 34059724

Group type: EXPERIMENTAL
Intervention: NPKb + U50% (bio-chemical fertilizers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: U (100% chemical fertilizer as urea at 53.3 kg ha‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pb + U50% (biofertilizer with 50% urea)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no fertilization)
Number of subjects: 10
Study: 32038035

Group type: EXPERIMENTAL
Intervention: BEMPU bracelet (hypothermia monitoring device)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (no hypothermia monitoring device)
Number of subjects: 386
Study: 35853998

Group type: EXPERIMENTAL
Intervention: Risk score based on proteinuria, emergency procedures, and serum creatinine (1 point each).
Number of subjects: 1254
Study: 34252914

Group type: COMPARATOR
Intervention: Placebo-administered agent (subcutaneous, endovenous, or oral)
Number of subjects: 5672

Group type: COMPARATOR
Intervention: Intravenous injection of eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody)
Number of subjects: 5672

Group type: COMPARATOR
Intervention: Oral topiramate
Number of subjects: 5672

Group type: COMPARATOR
Intervention: Subcutaneous monoclonal
Number of subjects: 5672

Group type: EXPERIMENTAL
Intervention: Multiple head injections (botulinum toxin)
Number of subjects: 5672
Study: 35137039

Group type: EXPERIMENTAL
Intervention: OPTIMAL programme
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 149
Study: 32772491

Group type: EXPERIMENTAL
Intervention: Investigational diet based on the Mediterranean diet and Dietary Approaches to Stop Hypertension diet (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Food exchange system-based diet (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Food exchange system-based diet (group C)
Number of subjects: 60
Study: 35325947

Group type: EXPERIMENTAL
Intervention: Contralateral normal external auditory canal (EAC) skin graft
Number of subjects: 13

Group type: COMPARATOR
Intervention: Scalp blade thick skin (Control)
Number of subjects: 13
Study: 32823606

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) with DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 0
Study: 35803039

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Supraglottic Device (SGD)
Number of subjects: 45
Study: 33065733

Group type: EXPERIMENTAL
Intervention: Screening for delirium using the Cornell Assessment of Pediatric Delirium
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Delirium-positive patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pain score increase (per point)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Total opioid exposure increase (per mg/kg/d)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: SBS less than 0
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pain medication or sedative administered in the previous 4 hours
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: No progressive physical therapy or ambulation schedule
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Parents not at bedside at time of data collection
Number of subjects: 181
Study: 32390503

Group type: EXPERIMENTAL
Intervention: Multiple imputation assuming a missing at random mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation assuming a missing not at random mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior distributions and shift parameters in the delta adjustment method
Number of subjects: 0
Study: 35718625

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI)
Number of subjects: 90
Study: 33484852

Group type: EXPERIMENTAL
Intervention: Body odor of ovulating women (OV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Body odor of pregnant women (PRG)
Number of subjects: 18
Study: 32936298

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 24349

Group type: COMPARATOR
Intervention: Oral anticoagulation alone
Number of subjects: 24349
Study: 35871497

Group type: EXPERIMENTAL
Intervention: RD12014
Number of subjects: 49

Group type: COMPARATOR
Intervention: Victoza
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 34293738

Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC) 1 tablet (1-g equivalent to 210 mg ferric iron) TID (3 g/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC) 2 tablets BID (4 g/day)
Number of subjects: 206
Study: 34605026

Group type: EXPERIMENTAL
Intervention: β‐OHB supplementation (30 mL or 12 g, thrice-daily for 14 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 36336532

Group type: EXPERIMENTAL
Intervention: Injector feeding group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bottle feeding group
Number of subjects: 62
Study: 33789264

Group type: EXPERIMENTAL
Intervention: WoundClot hemostatic gauze
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cotton gauze
Number of subjects: 24
Study: 32867735

Group type: EXPERIMENTAL
Intervention: Oxygen-sparing nasal reservoir cannula (OSNRC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard nasal cannula (SNC)
Number of subjects: 16
Study: 36175471

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) guided by intraoperative three-dimensional imaging of sacral CT and mobile C-arm fluoroscopy
Number of subjects: 52
Study: 33165539

Group type: EXPERIMENTAL
Intervention: Cannulas with long and narrow tubing (CLNT)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Short binasal prongs and masks (SPM)
Number of subjects: 166
Study: 35551683

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg, q.d. for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33734434

Group type: EXPERIMENTAL
Intervention: Idiopathic/genetic generalized epilepsies (IGEs)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Juvenile myoclonic epilepsy (JME)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Seizure-free patients with IGE
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Patients with persistent seizures
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Epilepsy with generalized tonic‐clonic seizures alone (EGTCS) and juvenile absence epilepsy (JAE)
Number of subjects: 402
Study: 36255254

Group type: EXPERIMENTAL
Intervention: 0.05% Dapivirine gel administered rectally using an applicator (2.5 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dapivirine gel self-administered as lubricant (up to 10 g)
Number of subjects: 16
Study: 33431374

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity with or without dietary advice)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 208
Study: 36361215

Group type: EXPERIMENTAL
Intervention: Integrative cognitive function improvement program administered to CN and MCI groups for six weeks.
Number of subjects: 52
Study: 34180278

Group type: EXPERIMENTAL
Intervention: CTFA-GRT (group reminiscence therapy based on Chinese traditional festival activities)
Number of subjects: 64
Study: 34918965

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Restrictive Fluid Therapy (Control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both GDFT and Restrictive Fluid Therapy
Number of subjects: 124
Study: 33280539

Group type: EXPERIMENTAL
Intervention: Condition 1: Challenged stereotypes about older adults
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Condition 2: Challenged stereotypes about careers working with older adults
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Condition 3: Challenged both stereotypes
Number of subjects: 845

Group type: COMPARATOR
Intervention: Control (Condition 4: Described careers in general)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Experimental conditions (Study 2)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Control (Study 2)
Number of subjects: 845
Study: 32268439

Group type: EXPERIMENTAL
Intervention: Pre-emptive administration of ibuprofen or paracetamol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Negative behaviour during anaesthesia
Number of subjects: 48
Study: 33074393

Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (HILT) + exercise therapy (ET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser (PL) + exercise therapy (ET)
Number of subjects: 40
Study: 35322719

Group type: EXPERIMENTAL
Intervention: Studies that questioned existing practices
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Studies that tested the practice in a randomized trial or encouraged future randomized testing
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Gastroenterology
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Obstetrics/Gynecology
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cardiovascular
Number of subjects: 98
Study: 32187789

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education plus cognition-targeted motor control training
Number of subjects: 64

Group type: COMPARATOR
Intervention: biomedically focused education and exercise therapy
Number of subjects: 64
Study: 35359035

Group type: EXPERIMENTAL
Intervention: 4% mangosteen gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 25
Study: 34538090

Group type: EXPERIMENTAL
Intervention: Maximum SBP (per 10 mm Hg increments)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Minimum SBP lower than 124 mm Hg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Minimum SBP higher than 124 mm Hg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Mean SBP
Number of subjects: 1161
Study: 34264128

Group type: EXPERIMENTAL
Intervention: Meal 1 (280 kcal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meal 2 (560 kcal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meals 1, 2, and 3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Changes in harmonic spectrum or heart rate
Number of subjects: 20
Study: 35102171

Group type: EXPERIMENTAL
Intervention: SAMiRNA-AR68 (AR68) at a low dose of 0.5 mg/ml applied three times per week for 24 weeks
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: SAMiRNA-AR68 (AR68) at a high dose of 5 mg/ml given once per week for 24 weeks
Number of subjects: 547

Group type: COMPARATOR
Intervention: Finasteride (control)
Number of subjects: 547
Study: 33737199

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (SL-BUP)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: 7-day extended-release injectable buprenorphine (CAM2038, XR-BUP)
Number of subjects: 2000
Study: 33908636

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously every 4 weeks (continuously treated)
Number of subjects: 1753

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously every 4 weeks (re-treated after treatment interruption)
Number of subjects: 1753

Group type: COMPARATOR
Intervention: Placebo maintenance (during treatment interruption)
Number of subjects: 1753
Study: 35585620

Group type: EXPERIMENTAL
Intervention: Good home massage compliance (practiced for at least 15 minutes for three or more days in a week)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (above median level)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (below median level)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (median 21.1%)
Number of subjects: 212
Study: 34171279

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 309

Group type: COMPARATOR
Intervention: 7+3 (cytarabine and daunorubicin chemotherapy)
Number of subjects: 309
Study: 32577871

Group type: EXPERIMENTAL
Intervention: EMR with the application of 0.3 ml of N-butyl-2-cyanoacrylate + methacryloxysulfolane—Glubran 2®
Number of subjects: 30

Group type: COMPARATOR
Intervention: EMR
Number of subjects: 30